Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ber 31, 2006. Shire has the leading portfolio of products in the US ADHD market.

PENTASA - Ulcerative colitis

US prescriptions of PENTASA for the year to December 31, 2007 were up 3% compared to the same period in 2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a 0.1% decrease in PENTASA's average market share from 17.3% in 2006 to 17.2% in 2007.

Sales of PENTASA for the year to December 31, 2007 were US$176.4 million, an increase of 28% compared to the same period in 2006 (2006: US$137.8 million). Sales growth is higher than prescription growth primarily due to restocking to normal levels in 2007 and the impact of price increases in November 2006 and August 2007.

LIALDA/MEZAVANT - Ulcerative colitis

Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a market share of 8.0% (average annual market share 3.9%). LIALDA's product sales for the year to December 31, 2007 were US$50.5 million. All initial launch stocks of LIALDA totaling US$34.3 million were recognised into revenue during the year to December 31, 2007.

The product was launched in the UK in November 2007, Canada in January 2008 and further launches are planned in the EU during 2008, subject to the successful conclusion of pricing and reimbursement negotiations. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.

Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at December 31, 2007, up from 17.6% as at December 31, 2006.

FOSRENOL - Hyperphosphatemia

FOSRENOL is now available in 25 countries and global sales totalled US$102.2 million for the year to December 31, 2007 (2006: US$44.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK,
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... H.C. Birnboim , DNA Genotek, ... Oragene gives higher DNA yields than other oral, collection ... g. In comparison, buccal, swabs may yield as little as 1.9 ... Introduction , The number of studies ...
, , Daniel G. Flowers and Lloyd A. Culp, Ph.D., , , , back to top...
... Julie Chang, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel ... Introduction , ... throughput and automating the sequencing process. This high-throughput , ... laboratories, driving such , achievements as the ...
Cached Biology Technology:DNA Yield with Oragene 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 3Comparison of Commercial Dye Terminator Removal Kits, Rev A 4Comparison of Commercial Dye Terminator Removal Kits, Rev A 5
(Date:7/13/2014)... New research raises the prospect of more effective treatments ... occurring in about half of all cancer patients, raising ... Cancer Institute. , Many strategies have been tried to ... patients can,t endure potentially life-saving treatments, but none have ... 13 advanced online edition of Nature , led ...
(Date:7/11/2014)... Society for Bone and Mineral Research awarded Michael F. ... (BUSM), with the 2014 Louis V. Avioli Award. Holick, ... is internationally known for revolutionizing the understanding of vitamin ... The award honors a member of the American Society ... to bone and mineral basic research. It is named ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... study, which was directed by Scripps Research Professor ... September 8 issue of The Journal of Biological ... than the one previously suggested-for the biosynthesis of ... endogenous cannabinoid ("endocannabinoid") anandamide. The high activity of ...
... Yujiang Song have discovered a better way to see where ... that produces novel hollow platinum nanostructures. , The research will ... German chemical journal Angewandte Chemie Int. Ed. In advance of ... the journal's web site. , Sandia is a National ...
... a common heavy metal are unable to obtain sufficient ... a new study presented at The American Physiological Society ... how cadmium, a heavy metal, reduces the oyster's tolerance ... during the summer when water temperatures rise. Half of ...
Cached Biology News:Study shows enzyme builds neurotransmitters via newly discovered pathway 2Sandia researchers discover way to see how a drug attaches to a cell 2Rising ocean temperatures, pollution have oysters in hot water 2Rising ocean temperatures, pollution have oysters in hot water 3Rising ocean temperatures, pollution have oysters in hot water 4
Adenylate kinase isoenzyme 6...
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Biology Products: